AU4862296A - Methods of decreasing serum calcium levels - Google Patents

Methods of decreasing serum calcium levels

Info

Publication number
AU4862296A
AU4862296A AU48622/96A AU4862296A AU4862296A AU 4862296 A AU4862296 A AU 4862296A AU 48622/96 A AU48622/96 A AU 48622/96A AU 4862296 A AU4862296 A AU 4862296A AU 4862296 A AU4862296 A AU 4862296A
Authority
AU
Australia
Prior art keywords
calcium levels
serum calcium
methods
decreasing serum
decreasing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU48622/96A
Other versions
AU701262B2 (en
Inventor
Susan M Boss
Willard H Dere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU4862296A publication Critical patent/AU4862296A/en
Application granted granted Critical
Publication of AU701262B2 publication Critical patent/AU701262B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Liquid Crystal Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Lowering serum calcium levels comprises admin. of 2-phenyl-3-aroyl benzothiophene deriv. of formula (I) or its salt or solvate. R1, R3 = H, Me, COAr or 1-6C alkoxy; Ar = opt. substd. Ph; R2 = pyrrolidine, hexamethylene imino or piperidino. (I) is pref. raloxifene.
AU48622/96A 1995-01-30 1996-01-29 Methods of decreasing serum calcium levels Ceased AU701262B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/380881 1995-01-30
US08/380,881 US5512583A (en) 1995-01-30 1995-01-30 Methods of decreasing serum calcium levels
PCT/US1996/001406 WO1996023501A1 (en) 1995-01-30 1996-01-29 Methods of decreasing serum calcium levels

Publications (2)

Publication Number Publication Date
AU4862296A true AU4862296A (en) 1996-08-21
AU701262B2 AU701262B2 (en) 1999-01-21

Family

ID=23502813

Family Applications (1)

Application Number Title Priority Date Filing Date
AU48622/96A Ceased AU701262B2 (en) 1995-01-30 1996-01-29 Methods of decreasing serum calcium levels

Country Status (19)

Country Link
US (1) US5512583A (en)
EP (1) EP0723780B1 (en)
JP (1) JPH10513184A (en)
KR (1) KR19980701731A (en)
CN (1) CN1086943C (en)
AT (1) ATE216232T1 (en)
AU (1) AU701262B2 (en)
CA (1) CA2211530A1 (en)
CZ (1) CZ286161B6 (en)
DE (1) DE69620661T2 (en)
DK (1) DK0723780T3 (en)
ES (1) ES2172633T3 (en)
HU (1) HUP9801335A3 (en)
NO (1) NO973470L (en)
NZ (1) NZ302546A (en)
PT (1) PT723780E (en)
RU (1) RU2176503C2 (en)
UA (1) UA43389C2 (en)
WO (1) WO1996023501A1 (en)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (en) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 New benzothiophene derivatives
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
DE4320896A1 (en) * 1993-06-24 1995-01-05 Denecke Rainer Dr Med Vet Product for the therapy and prophylaxis of dementias
US5478847A (en) * 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
TW398975B (en) * 1994-07-22 2000-07-21 Lilly Co Eli Pharmaceutical composition for inhibiting bone loss

Also Published As

Publication number Publication date
ATE216232T1 (en) 2002-05-15
EP0723780A2 (en) 1996-07-31
AU701262B2 (en) 1999-01-21
NZ302546A (en) 2000-06-23
WO1996023501A1 (en) 1996-08-08
DE69620661D1 (en) 2002-05-23
DE69620661T2 (en) 2002-11-14
KR19980701731A (en) 1998-06-25
CZ240397A3 (en) 1998-01-14
HUP9801335A2 (en) 1999-05-28
JPH10513184A (en) 1998-12-15
EP0723780B1 (en) 2002-04-17
DK0723780T3 (en) 2002-06-17
US5512583A (en) 1996-04-30
NO973470D0 (en) 1997-07-28
CA2211530A1 (en) 1996-08-08
CN1172432A (en) 1998-02-04
MX9705697A (en) 1997-10-31
CN1086943C (en) 2002-07-03
EP0723780A3 (en) 1996-09-11
HUP9801335A3 (en) 2000-03-28
PT723780E (en) 2002-08-30
CZ286161B6 (en) 2000-01-12
ES2172633T3 (en) 2002-10-01
RU2176503C2 (en) 2001-12-10
NO973470L (en) 1997-07-28
UA43389C2 (en) 2001-12-17

Similar Documents

Publication Publication Date Title
AU7579094A (en) Methods for the treatment of peri-menopausal syndrome
SI1465861T1 (en) Alpha-(n-sulphonamido)acetamide derivatives as beta-amyloid inhibitors
DE69332735D1 (en) Use of benzothiophenes for the treatment of hypercholesterolemia
AU8155894A (en) Methods of inhibiting thrombin
AU6530896A (en) Pyrrolidine derivatives having phospholipase a2 inhibitory activity
GB0318343D0 (en) No title
AU7578794A (en) Methods for inhibiting endometriosis
AU7583494A (en) Methods of inhibiting uterine fibrosis
AU8156394A (en) Methods for inhibiting LDL oxidation and atheroclerosis
AU8156194A (en) Methods of inhibiting dysfunctional uterine bleeding
AU7578994A (en) Methods for inhibiting cartilage degradation
AU7578694A (en) Methods for treating resistant neoplasms
AU6335194A (en) Method for producing benzylidene derivatives
AU4862296A (en) Methods of decreasing serum calcium levels
AU1710797A (en) Methods of modulating radical formation by mutant cuznsod enzymes
AU6985796A (en) Method of producing dihydroxypyrimidine derivatives
HU9600914D0 (en) 4-indolylpiperazinyl derivatives
UA26459C2 (en) INHIBITOR OF INFLUENCE OF AMYLOID PROTEINS
AP9600800A0 (en) 2-(Pyrazol-3-yl) carbapenem derivatives.
EP0711554A4 (en) Antidepressant
AU3409895A (en) Methods of inhibiting primary endometrial hyperplasia
PL322004A1 (en) Novel e. coli mutant of inhibited production or organic acids
EP0859758A4 (en)
HUP9902712A2 (en) Methods of increasing nitric oxide synthesis
MX9710147A (en) Herpes ribonucleotide reductase inhibitors.

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired